Manufacturer of Controlled Substances; Notice of Registration, 10678-10679 [05-4198]
Download as PDF
<![CDATA[
10678
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
Drug
Schedule
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Benzoylecgonine (9180) ...............
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
II
II
II
II
II
II
II
of controlled substances listed in
Schedules I and II:
Drug
II
II
II
II
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. sections 823(a) and
952(a) and determined that the
registration of Cerilliant Corporation to
import the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Cerilliant Corporation to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
sections 952(a) and 958(a), and in
accordance with 21 CFR 1301.34, the
above named company is granted
registration as an importer of the basic
class of controlled substance listed.
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4234 Filed 3–3–05; 8:45 am]
Schedule
N-Ethylamphetamine (1475) ........
4-Methoxyamphetamine (7411) ...
2,5-Dimethoxyamphetamine
(7396).
Difenoxin (9168) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Codeine (9050) .............................
Oxycodone (9143) ........................
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Dextropropoxyphene, bulk (9273)
Morphine (9300) ...........................
Thebaine (9333) ...........................
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Chattem Chemicals, Inc. to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Chattem Chemicals, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4230 Filed 3–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
BILLING CODE 4410–09–P
By notice dated September 28, 2004,
and published in the Federal Register
on October 13, 2004, (69 FR 60898),
Chattem Chemicals, Inc., 3801 St. Elmo
Avenue, Building 18, Chattanooga,
Tennessee 37409, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
DEPARTMENT OF JUSTICE
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated November 8, 2004,
and published in the Federal Register
on November 22, 2004, (69 FR 67962–
Frm 00088
Fmt 4703
Sfmt 4703
Drug
2,5-Dimethoxyamphetamine
(7396).
Amphetamine (1100) ....................
Phenylacetone (8501) ..................
Schedule
I
II
II
The company plans to manufacture
phenylacetone to be used in the
manufacture of the amphetamine. The
bulk 2, 5-dimethoxyamphetamine will
be used for conversion into noncontrolled substances.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of ISP,
Freetown Fine Chemicals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated ISP, Freetown Fine
Chemicals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4197 Filed 3–3–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
PO 00000
67963), ISP, Freetown Fine Chemicals,
Inc., 238 South Main Street, Assonet,
Massachusetts 02702, made application
by renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
By Notice dated November 1, 2004,
and published in the Federal Register
on November 10, 2004, (69 FR 65229),
Guilford Pharmaceuticals, Inc., 6611
Tributary Street, Baltimore, Maryland
21224, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
E:\FR\FM\04MRN1.SGM
04MRN1
10679
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices
manufacturer of Cocaine (9041), a basic
class of controlled substance listed in
Schedule II.
The company plans to manufacture a
cocaine derivative to be used as an
intermediate for the production of
Dopascan Injection. Cocaine derivatives
are a Schedule II controlled substance in
the cocaine basic class.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Guilford Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. DEA has
investigated Guilford Pharmaceuticals,
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with State
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
Any other such applicant and any
person who is presently registered with
VerDate jul<14>2003
19:07 Mar 03, 2005
Jkt 205001
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4202 Filed 3–3–05; 8:45 am]
BILLING CODE 4910–13–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
DEPARTMENT OF JUSTICE
Manufacturer of Controlled
Substances; Notice of Registration
Drug Enforcement Administration
By Notice dated September 16, 2004,
and published in the Federal Register
on September 30, 2004, (69 FR 58542–
58533), Lifepoint, Inc., 10400
Trademark Street, Rancho Cucamonga,
California 91730, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
Drug
Pursuant to section 1301.33(a) of Title
21 of the Code of Federal Regulations
(CFR), this is notice that on November
11, 2004, JFC Technologies, LLC, 100
West Main Street, Bound Brook, New
Jersey 08805, made application by
renewal to the Drug Enforcement
Administration (DEA) for registration as
a bulk manufacturer of the basic class of
controlled substances listed in Schedule
II:
Matthey Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
BILLING CODE 4410–09–P
By Notice dated November 22, 2004
and published in the Federal Register
on December 6, 2004, (69 FR 70470),
Johnson Matthey, Inc., Pharmaceutical
Materials, 2003 Nolte Drive, West
Deptford, New Jersey 08066, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of the basic
class of controlled substances listed in
Schedule II.
BILLING CODE 4410–09–P
Diphenozylate (9170) ....................
Hydrocodone (9193) .....................
Dated: February 23, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4227 Filed 3–3–05; 8:45 am]
Importer of Controlled Substances;
Notice of Registration
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–4198 Filed 3–3–05; 8:45 am]
Drug
DEA to manufacture such substances
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections being sent via regular mail
may be addressed, in quintuplicate, to
the Deputy Assistant Administrator,
Office of Diversion Control, Drug
Enforcement Administration,
Washington, DC 20537, Attention: DEA
Federal Register Representative, Liaison
and Policy Section (ODL); or any being
sent via express mail should be sent to
DEA Headquarters, Attention: DEA
Federal Register Representative/ODL,
2401 Jefferson-Davis Highway,
Alexandria, Virginia 22301; and must be
filed no later than May 3, 2005.
Schedule
Phenylacetone (8501) ..................
Raw Opium (9600) .......................
Concentrate of Poppy Straw
(9670).
II
II
II
The company plans to import the
listed controlled substances as raw
materials for use in the manufacture of
bulk controlled substances for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Johnson Matthey Inc. to import the basic
classes of controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971, at
this time. DEA has investigated Johnson
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Drug
Tetrahydrocannabinols (7370) .....
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Phencyclidine (7471) ....................
Benzoylecgonine (9180) ...............
Morphine (9300) ...........................
Schedule
I
II
II
II
II
II
The company plans to produce small
quantities of controlled substances for
use in drug test kits.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Lifepoint, Inc. to manufacture the listed
basic classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated
Lifepoint, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
E:\FR\FM\04MRN1.SGM
04MRN1
]]>Agencies
[Federal Register Volume 70, Number 42 (Friday, March 4, 2005)]
[Notices]
[Pages 10678-10679]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-4198]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated November 1, 2004, and published in the Federal
Register on November 10, 2004, (69 FR 65229), Guilford Pharmaceuticals,
Inc., 6611 Tributary Street, Baltimore, Maryland 21224, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk
[[Page 10679]]
manufacturer of Cocaine (9041), a basic class of controlled substance
listed in Schedule II.
The company plans to manufacture a cocaine derivative to be used as
an intermediate for the production of Dopascan Injection. Cocaine
derivatives are a Schedule II controlled substance in the cocaine basic
class.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Guilford Pharmaceuticals, Inc. to manufacture the listed basic classes
of controlled substances is consistent with the public interest at this
time. DEA has investigated Guilford Pharmaceuticals, Inc. to ensure
that the company's registration is consistent with the public interest.
The investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with State and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with
21 CFR 1301.33, the above named company is granted registration as a
bulk manufacturer of the basic classes of controlled substances listed.
Dated: February 22, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-4198 Filed 3-3-05; 8:45 am]
BILLING CODE 4410-09-P
